Clinical Trial Update: A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating OC Oral Solution for reducing sialorrhoea in Parkinson's disease; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Sialorrhoea

Drugs mentioned

• OC Oral Solution

Snippet

Sponsor: Orient Pharma Co., Ltd. | Conditions: Sialorrhoea | Phase 2 | Status: COMPLETED | Results posted: 2023-04-10